NCT04861467View on ClinicalTrials.gov

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

HNSCC

Interventions

DRUG

Camrelizumab

IV

Trial Locations (1)

100021

Cancer hospital, Chineses Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Chinese Academy of Medical Sciences

OTHER